NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Sample GSM2816585 Query DataSets for GSM2816585
Status Public on Oct 17, 2017
Title Control (patient with no osteoarthritis) CONTROL3
Sample type RNA
 
Source name Serum
Organism Homo sapiens
Characteristics gender: F
bmi: 22.00
Treatment protocol N/A
Growth protocol N/A
Extracted molecule total RNA
Extraction protocol Total RNA was extracted from serum samples using the RiboEXTMLS kit (GeneAll, Seoul, Korea). RNA quantity and quality were evaluated using a spectrophotometer (NanoDrop® ND-1000 UV-Vis, Nanogen Inc). RNA quantity and quality were evaluated using a spectrophotometer (NanoDrop® ND-1000 UV-Vis, Nanogen Inc.). Total RNA samples were spiked using the microRNA Spike-In Kit (Agilent Technologies Santa Clara, CA, USA) to assess the labeling and hybridization efficiencies. Labeling and hybridization were performed using the miRNA complete Labeling and Hybridization Kit (Agilent Technologies Santa Clara, CA, USA) according to manufacturer’s instructions. Samples were hybridized to the SurePrint G3 Human miRNA, 8X60K platform (miRBase release 21.0, Agilent Technologies Inc., Santa Clara, CA) containing probes for the detection of 2,549 human miRNAs. Images were scanned using Agilent Microarray Scanner (G2565CA) controlled by Agilent Scan Control 7.0 software. The signal after background subtraction was exported directly into Agilent Feature Extraction Software version 4.0.1.21 (Agilent Technologies, Santa Clara, CA). Normalization was performed using quantile algorithm. MicroRNAs were considered as differentially expressed (DE) if they obtained a p-value<0.05 and a False Discovery Rate (FDR)≤0.05.
Label Cy5
Label protocol Total RNA samples were spiked using the microRNA Spike-In Kit (Agilent Technologies Santa Clara, CA, USA) to assess the labeling and hybridization efficiencies. Labeling and hybridization were performed using the miRNA complete Labeling and Hybridization Kit (Agilent Technologies Santa Clara, CA, USA) according to manufacturer’s instructions.
 
Hybridization protocol Samples were hybridized to the SurePrint G3 Human miRNA, 8X60K platform (miRBase release 21.0, Agilent Technologies Inc., Santa Clara, CA) containing probes for the detection of 2,549 human miRNAs.
Scan protocol Images were scanned using Agilent Microarray Scanner (G2565CA) controlled by Agilent Scan Control 7.0 software.
Data processing The signal after background subtraction was exported directly into Agilent Feature Extraction Software version 4.0.1.21 (Agilent Technologies, Santa Clara, CA). Normalization was performed using quantile algorithm. MicroRNAs were considered as differentially expressed (DE) if they obtained a p-value<0.05 and a False Discovery Rate (FDR)≤0.05.
 
Submission date Oct 16, 2017
Last update date Jan 23, 2018
Contact name George I Lambrou
E-mail(s) [email protected]
Phone 00302107467427
Organization name National and Kapodistrian University of Athens
Department First Department of Pediatrics
Lab Choremeio Research Laboratory
Street address Thivon & Levadeias
City Athens
State/province Attiki
ZIP/Postal code 11527
Country Greece
 
Platform ID GPL21575
Series (1)
GSE105027 Circulating microRNA signature as novel biomarkers for osteoarthritis development

Data table header descriptions
ID_REF
VALUE Foreground Raw Signal Medians

Data table
ID_REF VALUE
1 158.00
2 70.00
3 70.00
4 63.50
5 68.00
6 66.00
7 58.00
8 58.50
9 63.00
10 61.00
11 188.50
12 null
13 170.00
14 177.00
15 169.00
16 160.00
17 169.50
18 177.00
19 null
20 null

Total number of rows: 62976

Table truncated, full table size 769 Kbytes.




Supplementary file Size Download File type/resource
GSM2816585_US81803240_257015612324_S02_miRNA_107_Sep09_1_3_Control3.txt.gz 2.7 Mb (ftp)(http) TXT
Processed data included within Sample table

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap